Adaptive Biotechnologies and Microsoft launch virtual ImmuneRACE study to inform novel COVID-19 diagnostics to address unmet needs in testing
Additional multimedia resources are available at https://www.adaptivebiotech.com/about-us/media-resources/.
There are currently two types of tests for COVID-19. PCR tests indicate the presence of live virus from a nose or throat swab, and serology tests indicate exposure to and potential immunity against the virus by measuring the presence of antibodies in the blood. Adaptive and
- Complementary or alternative diagnostic testing for individuals with known exposures or symptoms
- Ability to triage patients and inform treatment strategies based on risk
- Ongoing immunity surveillance testing of the population to inform decisions on restrictions
"We've spent the past decade learning how the adaptive immune system naturally detects and treats all disease, and we are well-positioned to apply our immune medicine platform specifically to COVID-19. We're hopeful that we can contribute important information that will become part of an immune scan to help reopen society," said
As part of the study, the partners will measure the presence of specialized cells of the immune system in the blood, called T cells, that identify the disease early on and proliferate to combat the infection. Together, Adaptive and
"We are dedicated to being part of the solution against COVID-19," said
In March, the companies announced an expansion of their existing partnership to use machine learning to map the immune system response to many different diseases, including infectious diseases, autoimmune disorders and cancer, at scale to study COVID-19. The information obtained from study participants, including how the immune system identifies the virus and how people are responding to the virus, will be integrated with data obtained from samples provided by hospitals and other institutions across the globe. The accuracy of the immune response signature will be continually improved and updated online in real time as more study samples are sequenced and by using Microsoft's hyperscale machine learning capabilities and the Azure cloud platform.
Other industry leaders, including Illumina and Providence, have also joined forces with
How to Join ImmuneRACE
ImmuneRACE will enroll 1,000 individuals from more than 20 metropolitan areas in the
- Currently have COVID-19
- Have recently recovered from COVID-19
- Were exposed to someone diagnosed with COVID-19
If you decide to participate and qualify for the study, you will be asked to provide relevant information about your medical history, symptoms and previous diagnostic tests. Patients who qualify for the study can schedule a blood draw and swab collection in the convenience of their own home. The phlebotomist completing sample collection will be using appropriate personal protective equipment to safely conduct the visit when entering participant's homes.
Every effort will be made to ensure confidentiality of protected health information in accordance with HIPAA. Those wanting to participate or learn about more ways to join in the fight against COVID-19 should visit www.ImmuneRACE.com.
About the Adaptive and
Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as the global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. To learn more, visit www.illumina.com and follow @illumina.
Providence is a national, not-for-profit Catholic health system comprising a diverse family of organizations and driven by a belief that health is a human right. With 51 hospitals, 1,085 physician clinics, senior services, supportive housing and many other health and educational services, the health system and its partners employ more than 119,000 caregivers serving communities across seven states –
View original content to download multimedia:http://www.prnewswire.com/news-releases/adaptive-biotechnologies-and-microsoft-launch-virtual-immunerace-study-to-inform-novel-covid-19-diagnostics-to-address-unmet-needs-in-testing-301052888.html
Microsoft Media Relations, WE Communications for Microsoft, (425) 638-7777, email@example.com, Beth Keshishian, Adaptive Media, (917) 912-7195, firstname.lastname@example.org, Lynn Lewis or Carrie Mendivil, Adaptive Investor, (415) 937-5405, email@example.com